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Purpose: Leuprorelin is a well known luteinizing hormone releasing hormone ag-
onist. However, there are insufficient data on the efficacy and safety of high dose 
leuprorelin acetate, especially in Asian patients with prostate cancer. We aimed to 
investigate the safety and efficacy of leuprorelin acetate 22.5 mg administered at 
three-month intervals in patients with prostate cancer. Materials and Methods: In 
an open, prospective clinical trial enrolling 47 patients, we aimed to assess the effi-
cacy and safety of leuprorelin acetate 22.5 mg in treating patients with histologi-
cally confirmed prostate cancer. The primary objective of this study was to evalu-
ate the efficacy of the leuprorelin acetate 22.5 mg in producing and maintaining 
castration levels of testosterone over a 6-month follow-up period and to determine 
its safety profile. Results: All 42 patients achieved serum testosterone levels with-
in the castration range by 4 weeks. A breakthrough response was observed in one 
of 36 patients by 8 weeks. However, this patient was medically castrated by 12 
weeks. There were no significant prostate-specific antigen (PSA) or testosterone 
changes according to clinical stage or body mass index. Twenty adverse events 
(AEs) in 15 of 42 patients (35.7%) were observed during this study. The most com-
mon AEs were hot flushes (n=4, 20.0%) with mild intensity, pain (n=2, 10.0%), and 
infection (n=2, 10.0%). No patient withdrew from the study due to AEs. Conclu-
sion: Leuprorelin acetate 22.5 mg was shown to be effective and safe in Asian pa-
tients with prostate cancer, even though sexual function decreased.
Key Words:   Prostate cancer, luteinizing hormone releasing hormone agonist, ad-
verse events
INTRODUCTION
In Korea, the incidence of prostate cancer has rapidly increased, and the increased 
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fect EF (e.g., phophodiesterase type 5 inhibitors); history of 
psychological disease, drug or alcohol dependence; men 
who suffered from any disease affecting testosterone levels; 
presence of another primary malignant neoplasm; men who 
suffered from known or suspected vertebral metastasis with 
risk of spinal compression; hypersensitivity to any of the 
study drugs or LHRH agonists; and history of participation 




This study comprised a 2-week screening period and a 24-
week therapeutic period. Patients who had histologically-
confirmed prostate cancer and provided informed consent 
were screened for 2 weeks. Patients eligible for participa-
tion in the study were added to the intent-to-treat (ITT) 
populations. 
During the therapeutic period, patients received two subcu-
taneous doses of leuprorelin acetate (Eligard® 22.5 mg Ha-
nAll Biopharmaceutical Co., Ltd., Seoul, Korea) at 12-week 
intervals for a total of 24 weeks. Efficacy and safety assess-
ments were performed at 4, 8, 12, and 24 weeks, and quality 
of life (QOL), penile length, and testis volume were assessed 
before treatment and at each visit. In particular, measurement 
of penile length and testis volume were performed at three 
hospital sites, and the values for a total of 18 patients were 
assessed. The use of concomitant medications was monitored 
throughout the study period. 
Efficacy, safety, and QOL assessments
Efficacy was assessed by determining the percentage of pa-
tients who achieved serum testosterone levels below the 
castration range (≤50 ng/dL) at 4 weeks and maintained 
castration during the study period without a breakthrough 
response, which was defined as serum testosterone level 
>50 ng/dL, occurring after castration. 
Safety assessments included regular examination for po-
tential adverse events using the WHO classification; labora-
tory abnormalities including hematology, coagulation and 
blood chemistry at 4, 8, 12, and 24 weeks; and blood pres-
sure. Patients were assessed before each injection unless 
otherwise stated. Investigators assessed the relationship be-
tween treatment and adverse events. Vital signs were also 
evaluated 2 and 4 hours after injection at day 1 and week 12. 
QOL was evaluated before treatment and at 4, 8, 12, and 
24 weeks using the Expanded Prostate Cancer Index (EPIC) 
sexual function domain.7 Patient self-assessment of bone 
incidence rate is highest among all forms of malignancy.1 
With widespread prostate-specific antigen (PSA) screening, 
localized prostate cancer has exhibited the greatest increas-
es in incidence rate among prostate cancer cases.2 PSA 
screening has facilitated discovery of a higher incidence of 
prostate cancer, as well as stage migration.3 From the CaP-
SURE database, despite early detection efforts and result-
ing stage migration in prostate cancer treatment, disease re-
currence still develops in a significant proportion of patients 
after radiation therapy or radical prostatectomy.4 
Androgen deprivation therapy (ADT) for prostate cancer 
was first introduced by Huggins and Hodges,5 and ADT re-
mains one of the most effective palliative treatments for pa-
tients with prostate cancer. Luteinizing hormone-releasing 
hormone (LHRH) agonists act by down-regulating the pitu-
itary gland, thereby suppressing secretion of luteinizing hor-
mone and follicular stimulating hormone from the testis.6 
Among several LHRH agonists, leuprorelin acetate 22.5 mg 
is a subcutaneous formulation designed to deliver 22.5 mg 
of leuprorelin acetate over 3 months and suppress serum tes-
tosterone levels over a 3-month period. However, there are 
insufficient data concerning the efficacy and safety of high 
dose leuprorelin acetate, especially in Asian patients with 
prostate cancer. Therefore, we aimed to investigate the safe-
ty and efficacy of leuprorelin acetate 22.5 mg administered 
at three-month intervals in patients with prostate cancer.  
MATERIALS AND METHODS
　　　
This multicenter (seven sites) study was designed to assess 
open-label, non-comparative administration of three month-
ly doses of leuprorelin acetate. The study protocol was ap-
proved by the institutional review boards of each center. 
Potential candidates provided written informed consent be-
fore participating in the screening. 
Patients
Between August 2011 and May 2012, 47 patients who had 
histologically-confirmed prostate cancer were enrolled in 
this prospective study. Eligible patients included men with 
an Eastern Cooperative Oncology Group performance sta-
tus of 0, 1, or 2, and no exposure to LHRH agonists, estro-
gens, anti-estrogens, antiandrogens, steroids or chemothera-
peutic agents within 3 months of participating in the study. 
Exclusion criteria consisted of a history of penile, urethral, 
or scrotal surgery; current use of medications known to af-
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of study medication, provided that they had safety data. 
Safety and QOL analyses were performed on the ITT popu-
lation. The statistical comparisons consisted of post hoc 
analyses of the effects of baseline parameters on mean 
change in penile length (cm) and testis volume (cc) to each 
post-baseline assessment up to and including 24 weeks. Dif-
ferences between penile length and testis volume measure-
ments before and after treatment were evaluated using Bon-
ferroni-corrected Wilcoxon’s signed-rank tests. Statistical 





Patient demographics are shown in Table 1. Fourteen out of 
42 patients had clinically localized prostate cancer, and 21 
and 7 patients had locally advanced and metastatic prostate 
cancer. 
Efficacy 
All of the 42 patients achieved serum testosterone levels 
within the castration range by 4 weeks. A breakthrough re-
sponse was observed in one of 36 patients by week 8; how-
ever, this patient was medically castrated by 12 weeks. 
Medical castration was achieved in all patients by 12 weeks 
and maintained up to 24 weeks. The mean PSA and testos-
terone changes after leuprorelin acetate treatment according 
to clinical stage are shown in Table 2. There were no signif-
icant PSA or testosterone changes according to clinical 
stage or body mass index. 
Safety
No deaths were reported during this study. Twenty adverse 
events (AEs) in 15 patients among 42 patients (35.7%) 
were observed during this study. The most common AEs 
were hot flushes (n=4, 20.0%) of mild intensity, pain (n=2, 
10.0%), and infection (n=2, 10.0%). No patient withdrew 
from the study due to AEs (Table 3). 
Genitalia changes and QOL assessment 
Before treatment, the mean values for stretched penile 
length and testis volume (right and left) were 8.87±2.79 cm 
and 12.65±4.57 cc (right) and 16.52±23.17 cc (left), respec-
tively. After ADT treatment, significant decreases in stretched 
penile length and testis volume were recorded: 8.14±2.83 
cm and 7.07±2.67 cc (right) and 6.93±1.94 cc (left), respec-
pain, urinary pain, and urinary symptoms was determined 
throughout the study using a visual analog scale of 1 (no 
pain or no difficulty) to 10 (worst possible pain or very dif-
ficult). Penile length was measured by the same investiga-
tor with a paper ruler and was recorded to the nearest 0.5 
cm. To avoid inter-observer variation, we used a spring scale 
to assure that each measurement was taken with a uniform 
stretching force (450 gm) using a technique previously de-
scribed by Chen, et al.8 The measurements were conducted 
in a dimly lit and warm private room, with the patient in a 
supine position. Stretched penile length was measured from 
the pubo-penile skin junction to the tip of the glans, while 
applying perpendicular tension. Testis volume was mea-
sured by an ultrasound. The largest length, width and depth 
were measured, and volume was calculated using the for-
mula V=/6×H×D×W.9
Statistics 
Data were analyzed using SPSS software (version 16.0, 
SPSS Inc., Chicago, IL, USA), with the efficacy analysis uti-
lizing the ITT population, which included all randomized 
patients, regardless of protocol deviations, except for those 
who had missing testosterone values at 4 weeks. The safety 
analysis included all patients who received at least one dose 
Table 1. Patient Demographics and Disease Characteristics
Characteristics No. of patients (%)
Age (yrs)     71.0±7.6 (52-89)
Height (cm) 165.81±5.84 (154.0-180.0)
Weight (kg)     67.3±10.1 (47.0-86.2)
PSA (ng/mL)     67.9±130.8 (0.31-579.00)
Clinical T stage (N)
    ≤T2c 14 (33.3)
    T3 23 (54.8)
    T4   5 (11.9)
Clinical N stage (N)
    Nx   1 (2.4)
    N0 27 (64.3)
    N1 14 (33.3)
Clinical M stage (N)
    Mx   5 (11.9)
    M0 30 (71.4)
    M1   7 (16.7)
ECOG performance status 
    0 32 (76.2)
    1   8 (19.0)
    2   2 (4.8)
PSA, prostate-specific antigen; ECOG, Eastern Cooperative Oncology 
Group.
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level delays the achievement of castration testosterone levels 
with leuprorelin.13 An additional report suggested that pa-
tients with higher baseline testosterone levels receiving a 
GnRH agonist may be at increased risk of tumor stimula-
tion and clinical flare.14 Notwithstanding, the present results 
suggest that a high dose of leuprorelin may induce castra-
tion more rapidly than other GnRH agonists, possibly due 
to differences in dose. 
Reportedly, greater BMI is associated with higher serum 
levels of total testosterone during GnRH agonist treatment 
than normal BMI.15 Obese men had total and free testoster-
one levels 1.8-fold and 2.3-fold greater than normal men 
after 48 weeks of GnRH agonist treatment, respectively. 
Other investigators have reported failure to maintain castra-
tion testosterone levels during GnRH agonist therapy.16,17 
However, in our study showed, obese patients (BMI >25 
kg/m2) achieved serum testosterone levels within the castra-
tion range by 24 weeks, contradictory to previous results. 
This result may be due to ethnic differences of lower BMI in 
tively (p=0.046, 0.001). In regards to sexual function as-
sessed on the EPIC questionnaire, statistically significant 
increases in erection problems were noted (p<0.01). Uri-
nary difficulty via patient self-assessment was significantly 
reduced at 24 weeks compared with that at baseline 
(p<0.01, -1.07±1.48). 
DISCUSSION
Eligard is a leuprorelin acetate formulation developed to in-
crease the proportion of patients who achieve castration lev-
els of testosterone and to reduce the occurrence of break-
through responses, without increasing side effects. Eligard 
has twice the amount of leuprorelin found in other leupro-
relin-based products and is available in three doses: 7.5 mg 
(0.25 mL), 22.5 mg (0.375 mL), and 45 mg (0.375 mL).10 
In a previous clinical trial,11 Eligard was shown to be highly 
effective in reducing mean testosterone levels to below cas-
tration levels established by the FDA (≤50 ng/dL). Break-
through was also infrequent and transient compared to our 
study. However, Heyns, et al.12 reported that repeated expo-
sure to a higher dose was more likely to cause an escape as 
a result of weak desensitization of pituitary GnRH recep-
tors. These contradictory results might be related to racial 
disparities. Further studies should address the mechanisms 
underlying the differences in the clinical responses to ADT 
between Asian people and Caucasian people.  
Our study revealed that castration levels of testosterone 
could be achieved after treatment with leuprorelin acetate, re-
gardless of baseline testosterone or clinical stage. The mean 
baseline testosterone level was 3262 ng/dL in 14 localized 
prostate cancer patients, and it decreased to 13.6 ng/dL at 4 
weeks after treatment with leuprorelin acetate. Nevertheless, 
another study reported that a higher baseline testosterone 
Table 2. Serum Testosterone Level and PSA Concentration during Treatment with Subcutaneous Injections of Leuprorelin 
Acetate Given at 3-Month Intervals, from Baseline through Month 6, by Clinical Stage








N (number) 42 14 21     7     42 14   21     7
Baseline 67.9 5.7 41.0 269.0 1370.2 3262.4 388.7 391.4
4 wks 15.5 3.4 11.0   51.5     15.6     13.6   17.7   13.4
8 wks   4.1 1.8   4.3     8.1     15.1     20.5   12.0   13.0
12 wks   3.1 1.5   2.9     6.9     12.8     15.0   12.3     9.8
24 wks   3.0 1.4   2.3     8.1       8.4       7.6     9.1     7.9
PSA, prostate-specific antigen.
By paired t-test or Wilcoxon signed rank test.
Table 3. Treatment-Related Adverse Events 
Number (%)
Hot flushing   4 (20) 
Infection   2 (10)
Pain   2 (10)
Calculus urethral   1 (5)
Nocutria   1 (5)
Hypertension   1 (5)
Tinnitus   1 (5)
Dyspepsia   1 (5)
Acute hepatitis   1 (5)
Fracture   2 (10)
Diabetes mellitus   1 (5)
Insomnia   1 (5) 
Cough   1 (5)
Pruritis   1 (5)
Total 20 (100)
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The high-dose LHRH agonist used in this study has been 
widely utilized in Western countries for 10 years, but is not 
yet utilized with Asian populations. According to a previ-
ous study,18 Asian people had higher testosterone levels, but 
a lower ratio of dihydrotestosterone to testosterone than Af-
rican-American or Caucasian men. In addition, Asian peo-
ple have a longer amino-terminal trinucleotide repeat length 
of the androgen receptor gene, which is associated with the 
incidence and severity of prostate cancer.19 However, in the 
present study, leuprorelin acetate at 22.5 mg effectively sup-
pressed serum testosterone levels despite racial differences, 
in comparison to other studies.11,20 Therefore, racial differ-
ences in sex hormone levels and the aggressive biology of 
prostate cancer in Korean people do not seem to adversely 
affect responses to ADT. 
In our study, the most common AE was hot flushes (n=4, 
20.0%). The incidences of AEs were relatively lower com-
pared to those reported in another study,19 even though our 
study was conducted with a double-dosed LHRH agonist. 
These results demonstrate that high-dose leuprorelin acetate 
did not induce higher AEs compared with low-dose leupro-
relin acetate. 
This prospective study had some limitations. Our study 
had a relatively short follow-up period and small sample 
size. In addition, we did not assess tumor responses after 
ADT treatment because of the difficulty of assessing this 
endpoint in men with PCa. Furthermore, future studies are 
needed to clarify the relationship between the extent of tes-
tosterone suppression, time to cancer progression, and can-
cer-specific survival. 
In the present study, medical castration was achieved in 
all patients by 12 weeks and maintained up to 24 weeks. 
Leuprorelin acetate 22.5 mg was shown to be effective and 
safe in Asian patients with prostate cancer, even though 
sexual function decreased during the study. Further long 
term follow up study is needed to confirm our results. 
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